Dicerna Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Dicerna Pharmaceuticals, Inc. (DRNA) is a biopharmaceutical company focused on the discovery, development and commercialization of ribonucleic acid interference (RNAi)-based therapeutics using its proprietary GalXC RNAi platform. The company leverages GalXC technology to silence disease-causing genes in the liver and other tissues for rare, cardiometabolic, viral, chronic liver and complement-mediated diseases; neurodegenerative diseases; pain; and oncology. Core product candidates include nedosiran for primary hyperoxaluria; RG6346 for chronic hepatitis B virus infection; belcesiran for alpha-1 antitrypsin deficiency-associated liver disease; and DCR-AUD for alcohol use disorder, alongside discovery programs such as DCR-PDL1 and DCR-STAT3 for oncology. Founded in 2006 and headquartered in Lexington, Massachusetts, Dicerna operates primarily in the United States with facilities in Cambridge, Massachusetts, and Boulder, Colorado. Dicerna entered a major strategic collaboration with Novo Nordisk in 2019 to co-develop RNAi therapies targeting over 30 liver cell targets for cardio-metabolic disorders, including non-alcoholic steatohepatitis, type 2 diabetes and obesity, valued at up to $607 million. In November 2021, Novo Nordisk acquired Dicerna for approximately $3.3 billion, completing the transaction in December 2021 and integrating it as a wholly-owned subsidiary, with Dicerna's common stock delisted from Nasdaq; this acquisition enhances Novo Nordisk's RNAi capabilities across its therapeutic areas, including ongoing pipeline advancement.
Company News
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
Shares of RNAi Drug Companies Pop After Novo Lays Out $3.3 Billion for Dicerna
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Dicerna Pharmaceuticals, Inc. - DRNA
Novo Nordisk (NVO) Set to Acquire Dicerna for $3.3 Billion
SHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo Nordisk
Dicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%
Why Dicerna Pharmaceuticals Stock Is Rocketing Higher Today
LCID, RIVN, FSR: Why Are EV Stocks Down Today?
Shareholder Alert: Ademi LLP investigates whether Dicerna Pharmaceuticals, Inc. has obtained a Fair Price in its going private transaction with Novo Nordisk
Dicerna Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dicerna Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – DRNA
Dicerna Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Dicerna Pharmaceuticals, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – DRNA
DRNA Stock: The $3B Novo Nordisk Deal That Has Dicerna Pharma Shares Skyrocketing Today
Novo Nordisk Swallows Dicerna In $3.3B Buyout: All You Need To Know
Why Novo Nordisk (NVO) Is Buying Dicerna Pharmaceuticals (DRNA) For $3.3 Billion
Novo Nordisk strikes $3.3 billion to buy research partner Dicerna Pharmaceuticals
Novo Nordisk to Acquire Dicerna